At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Active treatment with a high dose of BGS649 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Double-dummy, Placebo-controlled Study of Oral BGS649 Monotherapy Assessing Safety and Tolerability in Patients With Moderate to Severe Endometriosis
In Brief
A Phase 2 clinical trial evaluating Active treatment with a high dose of BGS649, Active treatment with a low dose of BGS649, and 1 other intervention for Endometriosis. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This study will assess the safety and tolerability of BGS649 in women with moderate to severe endometriosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedAug 2010
Primary CompletionSep 2011
TodayJul 2026
First PostedAug 27, 2010
Enrollment StartJul 1, 2010
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.8 years ago
Interventions
Active treatment with a high dose of BGS649drug
Active treatment with a low dose of BGS649drug
Placebo treatment to blind studydrug